- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01831856
Efficacy and Safety Study of F373280
June 13, 2019 updated by: Pierre Fabre Medicament
Efficacy and Safety Study of F373280 for Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation and Chronic Heart Failure. International, Multicentric, Randomised, Double-blind, Placebo Controlled Study.
The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
135
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Karlovy Vary, Czechia
-
Praha 2, Czechia, 128 08
-
Praha 5 - Motol, Czechia
-
-
-
-
-
Budapest, Hungary, 1122
-
Budapest, Hungary, 1032
-
Budapest, Hungary, 1096
-
Budapest, Hungary, 1023
-
-
-
-
-
Augusta, Italy
-
Brescia, Italy
-
Foggia, Italy
-
Terni, Italy
-
Verona, Italy
-
-
-
-
-
Grodzisk Mazowiecki, Poland
-
Radom, Poland
-
Sandomierz, Poland
-
Warszawa, Poland, 03-242
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
Santiago de Compostela, Spain
-
Tarragona, Spain
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or women aged more than 18 years (inclusive)
- Patients with current episode of persistent Atrial Fibrillation (AF) between 7 days and 6 months duration for whom electrical cardioversion is warranted
- Previous history of first documented episode of persistent AF.
- Previous history of ischemic or non ischemic heart failure
- New York Heart Association (NYHA) class I or II chronic heart failure at selection and at inclusion
Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
- an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
- and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
- and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
- On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
- Left atrial area ≤ 40 cm² at selection and at inclusion
- Patients treated or having to be treated by vitamin K antagonist
For female patient of child-bearing potential:
- In all the countries except Italy:
- Use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
Documented as surgically sterilized
- In Italy only:
- Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
- Use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
- Documented as surgically sterilized.
- For female patient of child-bearing potential: negative urine pregnancy test at inclusion
- For male with a child-bearing potential partner (In Italy only):
- Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
- Use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.
Ethical / legal considerations:
- Having signed his/her written informed consent,
- Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)
Exclusion Criteria:
- No previous history of first documented episode of persistent AF
- More than two successful cardioversions (electrical or pharmacological) in the last 6 months
- Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
- NYHA class III or IV heart failure at selection or at inclusion
- Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
- Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
- Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 ml/min) at selection
- Bradycardia (HR ≤ 50 bpm)
- Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
- Cardiac surgery within 3 months before selection or planned during the study duration
Criteria related to treatments:
- Previously ineffective pharmacological or electrical cardioversion
- Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, betablockers, calcium-blockers
- Concomitant treatment with oral amiodarone or dronedarone from selection
- Concomitant treatment with intravenous amiodarone from selection
- Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
- Treatment with any Polyunsaturated Fatty Acid (PUFA) within the last 3 months
- Dietary supplement with ω 3 or ω 6 according to investigator's judgement
- Having undergone any form of ablation therapy for AF
- Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel
Other criteria:
- Patient liable not to comply with protocol instructions and/or with treatment, in the investigator's opinion
- Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
- Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
- Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
- Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
- Breastfeeding female patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Oral administration, one capsule each evening with dinner.
|
Experimental: F373280
|
Oral administration, one capsule each evening with dinner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Atrial Fibrillation (AF) Recurrence or Atrial Flutter Emergence Defined by the Time to First Episode of AF or Atrial Flutter Lasting for at Least 10 Minutes During the 20-week Follow-up After Visit 3 (Electrical Cardioversion (ECV) Visit).
Time Frame: from electrical cardioversion (Visit 3) to last follow-up visit (W24)
|
Time to first Atrial Fibrillation (AF) recurrence defined by the first episode of Atrial Fibrillation lasting for at least 10 minutes.
AF recurrences or atrial flutter emergences: 7-day continuous electrocardiogram (ECG; 5-leads/2 or 3 channels) ambulatory recording (Holter ECG) between Visit 3 (Electrical Cardioversion Visit) and Visit 4 (Week 5).
Then, the follow-up was documented using the Transtelephonic ECG monitor (TTEM): one transmission every two days from Week 9 to Week 24.
For randomised patients with spontaneous cardioversion before Electrical Cardioversion, the recurrence of AF or the emergence of atrial flutter was assessed after Visit 3 (from Week 5).
Moreover, during this TTEM period, if the patient experienced any AF or atrial flutter symptoms, it was recorded and documented using the TTEM.
|
from electrical cardioversion (Visit 3) to last follow-up visit (W24)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Karim Keddad, MD, PierreFabre Medicamment
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2013
Primary Completion (Actual)
April 3, 2017
Study Completion (Actual)
June 21, 2017
Study Registration Dates
First Submitted
April 11, 2013
First Submitted That Met QC Criteria
April 12, 2013
First Posted (Estimate)
April 15, 2013
Study Record Updates
Last Update Posted (Actual)
July 2, 2019
Last Update Submitted That Met QC Criteria
June 13, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F373280 CA 2 01
- 2012-003487-48 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on 1g of F373280
-
Institut National de la Santé Et de la Recherche...Completed
-
Orpha LabsUnknownGlycogen Storage Disease, Type 14Turkey
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland
-
Microbiome Health SciencesCompleted
-
University of TorontoCanadian Institutes of Health Research (CIHR)CompletedCardiovascular Disease | Diabetes
-
Sunnybrook Health Sciences CentreActive, not recruiting
-
Chonbuk National University HospitalCompletedOsteopeniaKorea, Republic of
-
Russell SwerdlowCompleted
-
Chinese University of Hong KongCompleted